Search

Your search keyword '"Alfredo Romano"' showing total 2 results
Start Over Author "Alfredo Romano" Journal advances in therapy
2 results on '"Alfredo Romano"'

1. Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

Author

Mustapha Tehfe, Scot Dowden, Hagen Kennecke, Robert El-Maraghi, Bernard Lesperance, Felix Couture, Richard Letourneau, Helen Liu, and Alfredo Romano

Subjects
Adult, Male, Antimetabolites, Antineoplastic, Canada, Neutropenia, endocrine system diseases, Paclitaxel, nab-Paclitaxel, Adenocarcinoma, Deoxycytidine, Albumins, MPACT, Antineoplastic Combined Chemotherapy Protocols, Metastatic pancreatic cancer, Humans, Pharmacology (medical), Original Research, Aged, Medicine(all), General Medicine, Middle Aged, Gemcitabine, Pancreatic Neoplasms, Treatment Outcome, Oncology, Subgroup analysis, Female, Erratum, Drug Monitoring
Abstract

Introduction The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [HR] 0.72; P

Published
2016

2. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

Author

Hagen F. Kennecke, Helen Liu, Alfredo Romano, Scot D. Dowden, Richard Letourneau, Mustapha Tehfe, Bernard Lespérance, Robert Hassan El-Maraghi, and Félix Couture

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, endocrine system diseases, Population, Subgroup analysis, Neutropenia, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, Pharmacology (medical), education, Adverse effect, Medicine(all), education.field_of_study, business.industry, Hazard ratio, General Medicine, medicine.disease, Gemcitabine, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Deoxycytidine, business, medicine.drug
Abstract

The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [HR] 0.72; P

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results